Prof. Remo Panaccione

University of Calgary

HOSPITALIZATION RATES IN PATIENTS WITH CROHN’S DISEASE AND DEEP REMISSION: DATA FROM THE 56-WEEK CHARM TRIAL
2013-01-01
English, Medical management, Inflammatory bowel disease, Abstract, 'IBD-ology', 2013
LONG-TERM EFFECTIVENESS OF ADALIMUMAB IN CROHN’S DISEASE: OBSERVATIONAL DATA FROM THE PYRAMID REGISTRY
2013-01-01
English, Medical management, Inflammatory bowel disease, Abstract, 'IBD-ology', 2013
PYRAMID REGISTRY: AN OBSERVATIONAL STUDY OF ADALIMUMAB IN CROHN’S DISEASE: RESULTS AT YEAR 5
2013-01-01
English, Medical management, Inflammatory bowel disease, Abstract, 'IBD-ology', 2013
LONG-TERM SAFETY OF VEDOLIZUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS OR CROHN’S DISEASE
2013-01-01
English, Medical management, Inflammatory bowel disease, Abstract, 'IBD-ology', 2013
Tailoring treatment to the individual patient: How to do it?
2009-01-01
English, Presentation, Clinical aspects, Crohn’s disease, Medical management, Colon, Surgical management, Small intestine, 2009
Mission: Rapid Action and Lasting Remission - Focus on Disease Progression in Ulcerative Colitis (Takeda Pharmaceuticals International AG)
2017-10-29
English, Presentation, Industry Sponsored Symposia, Takeda Pharmaceuticals International AG, Industry Sponsored Symposia, 2017
AbbVie - Are we ready to change the course of IBD?
2018-10-22
English, Presentation, Industry Sponsored Symposia, Industry Sponsored Symposia, 2018, AbbVie
Takeda -Revisiting treatment success in Crohn’s disease (Takeda Pharmaceuticals International AG)
2019-10-21
English, Presentation, Industry Sponsored Symposia, Takeda Pharmaceuticals International AG, Industry Sponsored Symposia, 2019